1. Anticancer Effects of Spiperone in C57BL/6 Mice with Emphysema and Lung Carcinoma.
- Author
-
Ermakova NN, Zhukova MA, Pan ES, Pan VY, Morozov SG, Kubatiev AA, Dygai AM, and Skurikhin EG
- Subjects
- Animals, Mice, Antineoplastic Agents pharmacology, Male, Lung drug effects, Lung pathology, Lung metabolism, Dopamine D2 Receptor Antagonists pharmacology, Dopamine D2 Receptor Antagonists therapeutic use, Receptors, Dopamine D2 metabolism, Lipopolysaccharides toxicity, Mice, Inbred C57BL, Spiperone pharmacology, Spiperone therapeutic use, Carcinoma, Lewis Lung drug therapy, Carcinoma, Lewis Lung pathology, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells pathology, Pulmonary Emphysema drug therapy, Pulmonary Emphysema pathology, Pulmonary Emphysema metabolism, Lung Neoplasms drug therapy, Lung Neoplasms pathology
- Abstract
The antitumor and antimetastatic activity of dopamine D2 receptor antagonists spiperone was studied in C57BL/6 mice in a model of combined pathology (emphysema and lung cancer). Emphysema was induced by administration of LPS and cigarette smoke extract. Lung cancer was induced by injection of Lewis lung carcinoma cells into the lung. It has been shown that under conditions of combined lung pathology, spiperone prevents inflammatory infiltration and emphysematous expansion of the lungs and reduces the size of the primary tumor node, the number of metastases, and the area of the lungs affected by metastases. Spiperone reduces the number of cancer stem cells (CSCs) in the lungs and blood of mice with combined pathology. CSCs isolated from the lungs and blood of mice with combined pathology treated with spiperone had a significantly lower potential to form a tumorosphere in vitro than CSCs from untreated mice with emphysema and lung carcinoma. Thus, blockade of dopamine D2 receptors is a promising approach for correcting combined lung pathology and can be used in the development of a method for treating lung cancer in patients with emphysema., (© 2024. Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF